20. Bivariate analysis for overall survival in chemotherapy trials.
| Overall survival for chemotherapy patients | Patients included | ESA versus control Unadjusted hazard ratio (95% CI) | ESA versus control Adjusted hazard ratio (95% CI) | P value LR‐Test* |
| Total | 10441 | 1.04 (95% CI 0.97‐1.11) | ‐ | ‐ |
| Hb at baseline (continuous) | 9945 | 1.04 (95% CI 0.97‐1.11) | 1.05 (95% CI 0.98‐1.12) | 0.0000 |
| Hb at baseline (categorical 1) | 9945 | 1.04 (95% CI 0.97‐1.11) | 1.05 (95% CI 0.98‐1.12) | 0.0000 |
| Hb at baseline (categorical 2) | 9945 | 1.04 (95% CI 0.97‐1.11) | 1.05 (95% CI 0.98‐1.12) | 0.0000 |
| Tumor (categorical 1) | 10399 | 1.04 (95% CI 0.97‐1.11) | 1.04 (95% CI 0.97‐1.11) | 0.0000 |
| Tumor (categorical 2) | 10399 | 1.04 (95% CI 0.97‐1.11) | 1.03 (95% CI 0.97‐1.11) | 0.0000 |
| Sex | 10441 | 1.04 (95% CI 0.97‐1.11) | 1.04 (95% CI 0.97‐1.11) | 0.0000 |
| Age (continuous) | 10430 | 1.04 (95% CI 0.97‐1.11) | 1.04 (95% CI 0.97‐1.11) | 0.0000 |
| Age (categorical) | 10430 | 1.04 (95% CI 0.97‐1.11) | 1.04 (95% CI 0.97‐1.11) | 0.0000 |
| Hct (continuous) | 7849 | 1.03 (95% CI 0.96‐1.11) | 1.04 (95% CI 0.97‐1.12) | 0.0000 |
| Hct (categorical) | 7849 | 1.03 (95% CI 0.96‐1.11) | 1.04 (95% CI 0.97‐1.12) | 0.0000 |
| Baseline serum EPO (continuous) | 3959 | 0.97 (95% CI 0.88‐1.07) | 0.97 (95% CI 0.88‐1.07) | 0.1538 |
| Baseline serum EPO (categorical) | 3959 | 0.97 (95% CI 0.88‐1.07) | 0.97 (95% CI 0.88‐1.07) | 0.0000 |
| ECOG (0 vs 1 vs 2 vs 3 vs 4) | 8057 | 1.04 (95% CI 0.97‐1.12) | 1.04 (95% CI 0.96‐1.12) | 0.0000 |
| ECOG (0,1,2 vs 3,4) | 8057 | 1.04 (95% CI 0.97‐1.12) | 1.04 (95% CI 0.97‐1.12) | 0.0000 |
| BMI (categorical) | 8882 | 1.02 (95% CI 0.95‐1.10) | 1.03 (95% CI 0.95‐1.10) | 0.0000 |
| History of thromboembolic events | 6667 | 1.04 (95% CI 0.95‐1.13) | 1.03 (95% CI 0.95‐1.12) | 0.0194 |
| History of cardiovascular events | 7369 | 1.04 (95% CI 0.96‐1.13) | 1.04 (95% CI 0.96‐1.13) | 0.0033 |
| History of hypertension | 6667 | 1.04 (95% CI 0.95‐1.13) | 1.03 (95% CI 0.95‐1.12) | 0.5565 |
| History of diabetes mellitus | 5579 | 1.04 (95% CI 0.95‐1.14) | 1.05 (95% CI 0.95‐1.15) | 0.0253 |
| Geographical region [region_cat] | 10053 | 1.03 (95% CI 0.97‐1.10) | 1.03 (95% CI 0.97‐1.11) | 0.1689 |
| Metastatic vs non‐metastatic | 8956 | 1.06 (95% CI 0.98‐1.13) | 1.04 (95% CI 0.97‐1.12) | 0.0000 |
| Time from cancer diagnosis to randomization | 3114 | 1.01 (95% CI 0.91‐1.13) | 1.01 (95% CI 0.91‐1.13) | 0.7895 |
*This test compares the adjusted with the unadjusted model. It takes into account the entire model, not only the overall hazard ratio.